Key Market Indicator:
F&G: 55
25.626,31 NASDAQ · 49.103,00 DOW · 6.906,59 S&P · 4.981,30 Gold · 65,07 BRENT

One Community. One Spirit. N#1 Broker.
all asset classes · all possibilities

Switch View
Hedge the Peak | Protect your Profits
US72941H4002
Filter zurücksetzen
© Globe Newswire
21.01.2026
ISIN: US72941H4002
Plus Therapeutics Inc
PSTV
LISTED
NASDAQ
Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, January 22, 2026 at 9:00 A.M. ET
Article
News Preview
HOUSTON, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ: PSTV) (the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announces that the Company will provide a business update on Thursday, January 22, 2026 before the mar...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.01.2026
ISIN: US72941H4002
Plus Therapeutics Inc
PSTV
LISTED
NASDAQ
Plus Therapeutics Announces Pricing of Upsized $15 Million Public Offering
Article
News Preview
HOUSTON, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ: PSTV) (the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announces the pricing of its underwritten public offering of 39,473,684 units, with each unit consisti...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.01.2026
ISIN: US72941H4002
Plus Therapeutics Inc
PSTV
LISTED
NASDAQ
Plus Therapeutics Announces Read Out of Type B Meeting with the FDA with Goal of Accelerating Approval of REYOBIQ™ for Leptomeningeal Metastases
Article
News Preview
On track to define optimal dosing interval and advance manufacturing scale up of REYOBIQ for pivotal trial readiness in late 2026 On track to define optimal dosing interval and advance manufacturing scale up of REYOBIQ for pivotal trial readiness in late 2026...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
More Info
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© Globe Newswire
11.12.2025
ISIN: US72941H4002
Plus Therapeutics Inc
PSTV
LISTED
NASDAQ
Plus Therapeutics Expands CNSide Assay Platform to State of California
Article
News Preview
CNSide Diagnostics now licensed in 48 U.S. States covering over 90% of the U.S. population CNSide Diagnostics now licensed in 48 U.S. States covering over 90% of the U.S. population...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
23.01.2026
© Globe Newswire
09.12.2025
ISIN: US72941H4002
Plus Therapeutics Inc
PSTV
LISTED
NASDAQ
Plus Therapeutics Announces Expansion of CNSide Team and Issuance of Inducement Grants
Article
News Preview
HOUSTON, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced two new hires to its team for CNSide Diagnostics, LLC, its wholly-o...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.12.2025
ISIN: US72941H4002
Plus Therapeutics Inc
PSTV
LISTED
NASDAQ
Plus Therapeutics Highlights Three REYOBIQ™ Clinical Data Presentations at 2025 WFNOS/SNO Annual Meeting
Article
News Preview
Cohort 1 data from multiple dose ReSPECT- Leptomeningeal Metastases (LM) trial showed no dosage limiting toxicity...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.12.2025
ISIN: US72941H4002
Plus Therapeutics Inc
PSTV
LISTED
NASDAQ
Plus Therapeutics to Present ReSPECT Phase 1 Dose Escalation Study Results for Leptomeningeal Metastases at the 2025 San Antonio Breast Cancer Symposium
Article
News Preview
Study findings to be featured in a poster spotlight presentation Study findings to be featured in a poster spotlight presentation...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.11.2025
ISIN: US72941H4002
Plus Therapeutics Inc
PSTV
LISTED
NASDAQ
Plus Therapeutics Announces Completion of U.S. FDA Meeting on Future Clinical Development Plans for REYOBIQ™ in Leptomeningeal Metastases
Article
News Preview
HOUSTON, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, announced it has completed a Type B meeting with the U.S. Food and Drug Administration (FDA) on November 7th...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.11.2025
ISIN: US72941H4002
Plus Therapeutics Inc
PSTV
LISTED
NASDAQ
Plus Therapeutics Secures National Coverage Agreement with Humana for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer
Article
News Preview
HOUSTON, Nov. 20, 2025 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), announced today that it has signed a national agreement with Humana, Inc. (NYSE: HUM), effective October 29, 2025, covering approximately 16 million people throughout the United States,...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.11.2025
ISIN: US72941H4002
Plus Therapeutics Inc
PSTV
LISTED
NASDAQ
Plus Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq’s Minimum Bid Price Requirement
Article
News Preview
No near-term Reverse Stock Split required to meet Bid Price Rule No near-term Reverse Stock Split required to meet Bid Price Rule...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.11.2025
ISIN: US72941H4002
Plus Therapeutics Inc
PSTV
LISTED
NASDAQ
Plus Therapeutics Highlights ReSPECT-LM Clinical Trial Results at 40th SITC Annual Meeting, Melanoma Research Foundation Brain Metastases Summit 4.0
Article
News Preview
Leptomeningeal metastases disease session features novel treatments in the horizon, REYOBIQ™ and ReSPECT-LM, and future directions and needs Leptomeningeal metastases disease session features novel treatments in the horizon, REYOBIQ™ and ReSPECT-LM, and future directions and needs...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.10.2025
ISIN: US72941H4002
Plus Therapeutics Inc
PSTV
LISTED
NASDAQ
Plus Therapeutics Reports Third Quarter Financial Results and Recent Business Highlights
Article
News Preview
US market introduction of the CNSide® CSF diagnostics platform, with first national coverage agreement with UnitedHealthcare...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
21.10.2025
ISIN: US72941H4002
Plus Therapeutics Inc
PSTV
LISTED
NASDAQ
Plus Therapeutics Updates on CNSide® Diagnostic Platform Launch
Article
News Preview
Expands commercial readiness and diagnostic, manufacturing footprint...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.09.2025
ISIN: US72941H4002
Plus Therapeutics Inc
PSTV
LISTED
NASDAQ
Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare Insurance Company for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer
Article
News Preview
HOUSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), announced today that it has signed a national agreement with UnitedHealthcare Insurance Company (NYSE: UNH), effective September 15, 2025, covering over 51 million people throughout th...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.09.2025
ISIN: US72941H4002
Plus Therapeutics Inc
PSTV
LISTED
NASDAQ
Plus Therapeutics Announces Additional $1.9 Million Advance Payment from CPRIT   
Article
News Preview
Non-dilutive payment is part of $17.6 million award granted for the Company’s leptomeningeal cancer targeted radiotherapeutic development program...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.09.2025
ISIN: US72941H4002
Plus Therapeutics Inc
PSTV
LISTED
NASDAQ
Plus Therapeutics Announces Successful Accreditation and Certification for Its CNSide® Diagnostics Clinical Laboratory
Article
News Preview
Certification critical to broad U.S. market release of the CNSide CSF Assay Platform...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.09.2025
ISIN: US72941H4002
Plus Therapeutics Inc
PSTV
LISTED
NASDAQ
Plus Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference
Article
News Preview
HOUSTON, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces that it will participate in the H.C. Wainwright 27th Annual Global Inves...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.08.2025
ISIN: US72941H4002
Plus Therapeutics Inc
PSTV
LISTED
NASDAQ
Plus Therapeutics Regains Compliance with Applicable Nasdaq Listing Criteria
Article
News Preview
No near-term Reverse Stock Split required to meet Bid Price Rule No near-term Reverse Stock Split required to meet Bid Price Rule...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.08.2025
ISIN: US72941H4002
Plus Therapeutics Inc
PSTV
LISTED
NASDAQ
Plus Therapeutics Presents Positive ReSPECT-LM Clinical Trial Results of REYOBIQ™ in Leptomeningeal Metastases
Article
News Preview
REYOBIQ produced a clinical benefit rate of over 75% in 3 clinically relevant outcome measures...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.08.2025
ISIN: US72941H4002
Plus Therapeutics Inc
PSTV
LISTED
NASDAQ
Plus Therapeutics Reports Stockholders’ Equity in Excess of $2.5 million in Compliance with Nasdaq Equity Requirements
Article
News Preview
Plus Therapeutics Reports Stockholders’ Equity in Excess of $2.5 million in Compliance with Nasdaq Equity Requirements...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.08.2025
ISIN: US72941H4002
Plus Therapeutics Inc
PSTV
LISTED
NASDAQ
Plus Therapeutics Reports Second Quarter Financial Results and Recent Business Highlights
Article
News Preview
Announced CNSide® CSF assay platform launch timeline...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.06.2025
ISIN: US72941H4002
Plus Therapeutics Inc
PSTV
LISTED
NASDAQ
Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, June 26, 2025 at 9:00 A.M. ET
Article
News Preview
HOUSTON, June 25, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces that the Company will provide a business update on Thursday, June 26, 2025 be...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.05.2025
ISIN: US72941H4002
Plus Therapeutics Inc
PSTV
LISTED
NASDAQ
Plus Therapeutics Reports First Quarter Financial Results and Recent Business Highlights
Article
News Preview
Plus Therapeutics Reports First Quarter Financial Results and Recent Business Highlights...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.05.2025
ISIN: US72941H4002
Plus Therapeutics Inc
PSTV
LISTED
NASDAQ
Plus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q
Article
News Preview
Plus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.03.2025
ISIN: US72941H4002
Plus Therapeutics Inc
PSTV
LISTED
NASDAQ
Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
Article
News Preview
Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
11.03.2025
ISIN: US72941H4002
Plus Therapeutics Inc
PSTV
LISTED
NASDAQ
D. Boral Capital Served as Exclusive Placement Agent to Plus Therapeutics, Inc. (Nasdaq:PSTV) in Connection with its up to $15.0 Million Private Placement
Article
News Preview
HOUSTON, TX / ACCESS Newswire / March 11, 2025 / On March 4th, Plus Therapeutics, Inc. (Nasdaq:PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announced the pricing of a private placement with gross proceeds t...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.03.2025
ISIN: US72941H4002
Plus Therapeutics Inc
PSTV
LISTED
NASDAQ
Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds
Article
News Preview
Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.11.2024
ISIN: US72941H4002
Plus Therapeutics Inc
PSTV
LISTED
NASDAQ
Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Article
News Preview
Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.08.2024
ISIN: US72941H4002
Plus Therapeutics Inc
PSTV
LISTED
NASDAQ
Plus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
Article
News Preview
Plus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.05.2024
ISIN: US72941H4002
Plus Therapeutics Inc
PSTV
LISTED
NASDAQ
Plus Therapeutics Announces New Employment Inducement Grants
Article
News Preview
Plus Therapeutics Announces New Employment Inducement Grants...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.05.2024
ISIN: US72941H4002
Plus Therapeutics Inc
PSTV
LISTED
NASDAQ
Plus Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
Article
News Preview
Plus Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.05.2024
ISIN: US72941H4002
Plus Therapeutics Inc
PSTV
LISTED
NASDAQ
Plus Therapeutics Provides Highlights Regarding Leptomeningeal Metastases Acquisition and Topline Clinical Trial Data on the FORESEE Trial
Article
News Preview
Plus Therapeutics Provides Highlights Regarding Leptomeningeal Metastases Acquisition and Topline Clinical Trial Data on the FORESEE Trial...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.05.2024
ISIN: US72941H4002
Plus Therapeutics Inc
PSTV
LISTED
NASDAQ
Plus Therapeutics to Host Investor Call to Discuss Leptomeningeal Cancer Related Acquisition and Topline Clinical Trial Data from the FORESEE Trial
Article
News Preview
Plus Therapeutics to Host Investor Call to Discuss Leptomeningeal Cancer Related Acquisition and Topline Clinical Trial Data from the FORESEE Trial...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
Indices
DAX, DOW, S&P, FTSE...
Realtime Trading
With & without leverage
Currencies
EUR, USD, JPY, BRL, GBP ....
50 FX-Pairs
Top Conditions, Tied spreads, Mini/Micro
Commodities
Brent, WTI, Coffee, Wheat....
Long & Short
Crude oil, Agricultural & more
Metals
Gold, Silver, Palladium, Platinum
Hedging
Soft-,Heavy-, Precious Metals
Stocks & ETF
TSLA, NFLX, NVDA, MSFT, AAPL ....
Leveraged Equity Trading
USA, Europe, Asia
More information, click here

More sector specific news

Your Press Release is missing or you want share news over GICS11? Drop us a line.

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

XLB
XLE
XLU
XLY
XLF
XLP
XLV
XLK
XLC
XLI
XLRE
© 2026 Select Sector SPDRs
* * *
More Sector related Investment Ideas
XLB
XLE
XLU
XLY
XLF
XLP
XLV
XLK
XLC
XLI
XLRE
© 2026 WEBs Investments ETFs
About the newsfeed
#1
What types of information are provided on this portal - and what purpose does it serve?
The portal provides structured, stock market-relevant company information that is specifically assigned to a particular economic sector. The focus is on current announcements from official NewsWire sources, supplemented by company profiles, filter options by sector and sector-specific research aids. The aim is to offer an interested group of people a systematically structured research environment that improves their understanding of sector developments and corporate strategies.
#2
Why are companies categorized according to a certain system?
Financial markets consist of thousands of listed companies with very different business models. In order to create transparency and comparability, companies worldwide are assigned to standardized classifications. These classifications help investors to better analyze markets, identify sector-specific trends and make more targeted investment decisions.
#3
What classification standards exist for grouping companies?
There are various industry classifications that are used depending on the region or application. The best known include GICS (Global Industry Classification Standard), ICB (Industry Classification Benchmark), NAICS (North American Industry Classification System) and TRBC (Thomson Reuters Business Classification). Most institutional investors and ETFs worldwide use GICS or ICB as a benchmark.
#4
What classification standard is this financial information portal based on?
The portal uses the Global Industry Classification Standard (GICS), which was jointly developed by MSCI and S&P Dow Jones Indices. GICS is widely used in the institutional financial world and forms the basis for many global equity indices, ETFs and research systems.
#5
What exactly does GICS mean - and how is the system structured?
GICS stands for Global Industry Classification Standard. It is a hierarchical structure that divides listed companies worldwide into four levels: Sector, Industry Group, Industry Sector and Sub-Industry. In total, the system comprises 11 main sectors, over 60 industries and more than 150 sub-categories. It allows a consistent, internationally comparable analysis of economic activities.
#6
Why is GICS important in the financial world?
GICS offers a standardized language for investment decisions. It makes it possible to compare companies with similar business models - regardless of country, stock exchange or company size. Many investment funds, indices and research houses use GICS as a basis for portfolio construction, risk analysis or market screening. This means that it also makes sense for private investors to use this structure as a guide.
#7
Who decides which GICS sector a company is assigned to?
The allocation is made by the index providers MSCI and S&P Dow Jones on the basis of a company's main business segment. The decisive factor is the segment from which the company generates the majority of its sales or operating profit. Changes in the business model or strategic realignments can lead to a company being assigned to a different industry or even a different sector.
#8
What is meant by the GICS sector "Materials"?

The GICS "Materials" sector comprises companies that are active in the production, processing or refinement of raw materials. This includes industries such as chemicals, building materials, paper & forest products and the entire metallurgical and mining industry. The sector is highly cyclical and is particularly sensitive to economic fluctuations and changes in global demand.

#9
Which companies typically belong to the Materials sector?
Typical representatives are international groups from the areas of chemicals production (e.g. BASF), precious metal mining (e.g. Barrick Gold), building materials production (e.g. Heidelberg Materials) or industrial gases (e.g. Linde). The shares of these companies are often heavily dependent on commodity prices and play a central role in industrial value chains.
#10
Where does the company news on this page come from?
The news is based on verified and publicly available sources such as BusinessWire, GlobeNewswire, PR Newswire, EQS, Newsfile, ACCESSNewswire and other NewsWire services. These platforms are used by listed companies to publish mandatory ad hoc announcements, financial reports or strategic developments. All content is prepared in a structured manner and, if a corresponding categorization is possible, brought together in industry-specific clusters.
#11
How is the sector-specific mapping of messages carried out?
Categorization is based on structured metadata (e.g. ISIN, ticker, sector classification) and a combination of keyword analysis and GICS mapping. This ensures that all news is assigned to the correct sector and - if available - the correct sub-sector.
#12
Why is the materials sector particularly interesting for investors?
The Materials sector is closely linked to global industrial production and offers both cyclical growth opportunities and hedging opportunities against inflation and raw material shortages. In addition, many companies in this sector play a key role in future topics such as electromobility, the energy transition and sustainable building materials.
#13
What distinguishes this project from traditional financial information portals?
In contrast to generic portals, this project focuses exclusively and specifically on a particular sector. The advantage for interested investors: Sector-specific information, news, market movements and company profiles can be filtered and analyzed in a more targeted manner. This enables more in-depth research and greater relevance for thematic investment decisions.
#14
Are smaller companies also represented here or only large corporations?
The newsfeed takes into account both large caps and mid and small caps. As a clear mapping criterion is required in order to enable the most precise possible allocation to a cluster, the ISIN of the listed company is generally used for this purpose, provided that this can be made available or mapped via corresponding newsfeed parameters.
#15
How up-to-date are the displayed messages?
The content is updated regularly. The publication follows the publications of the information source, the NewsWire feeds of the underlying distributors. Incoming reports are automatically processed, classified and displayed on the page. Timestamps and source information ensure maximum transparency.
#16
Can I also filter the news by sub-sector?
Yes, this is a central feature of the site. Within a main sector, you can filter specifically for sub-sectors such as "Metals & Mining". For particularly popular industries or developments within a meta-sector, it is possible to deviate from standard clusters. Special categories with particular information value enable thematic analyses to be carried out even more precisely.
#17
Are there plans to process other metasectors in a similar way?
Yes, this financial information portal is part of an extensive project in which separate information portals are being created for all the main sectors. The aim is to provide investors with a systematic, sector-based research tool - regardless of index affiliation or provider perspective.
#18
Why do companies publish announcements via NewsWire services at all?
NewsWire services such as BusinessWire or PR Newswire fulfill a regulatory function: they enable companies to publish price-sensitive information publicly and without discrimination. In many countries, the use of such services is a prerequisite for fulfilling publication obligations under capital market law. They also enable companies to reach the media, analysts and investors in a targeted manner.
#19
Can private or inactive companies also appear in such notifications?
Generally not. The platform focuses exclusively on listed companies whose disclosures are based on regulatory requirements or corporate strategy measures. Although private or unlisted companies occasionally publish announcements, these are not systematically processed or classified here.
#20
What happens when a company changes its business model - does its sector classification also change?
Yes, as a rule - but not automatically. The responsible classification institutes (e.g. MSCI and S&P for GICS) regularly check the relevance and consistency of the classifications. If there is a significant change in a company's sales or profit profile, it may be reclassified to a different industry or even a different sector. This usually takes place after fixed review cycles or upon request.
#21
How is it ensured that a company is correctly categorized if it is active in several business areas?
The categorization is based on the dominant sales segment. If a company is active in several sectors but generates 70% of its turnover with chemical products, for example, it is assigned to the GICS sector "Materials" - even if it also has activities in the energy or transportation sector. In borderline cases, additional qualitative assessment criteria apply.
#22
Are there any legal risks in the further use of the displayed content?
The content comes from public sources, but is partially subject to copyright protection - particularly with regard to text structure and layout. The excerpts and links provided on this portal are made within the scope of permitted use (e.g. right to quote or editorial processing). However, commercial use by third parties is not permitted without the express permission of the original providers.
#23
Who can I contact if I have general questions or legal concerns?
A central contact point is available for general inquiries, information on company recordings, compliance issues or copyright-relevant aspects. In rare cases, for example in the case of erroneously published information or justified requests for deletion, a review and, if necessary, removal from the public feed can take place. Please only use the official contact option in the legal notice or at the bottom of the page.
#24
Is advertising or third-party content also displayed on the portal?
Yes, in defined areas the portal can display advertising content or product-specific information from third parties - for example on sector-related financial services, research offers or trading platforms. This content is clearly marked as advertising or partner information and is separate from the editorial or automatically processed company news.
#26
Can I give feedback on the platform or submit suggestions?
Absolutely - feedback is expressly welcome. The platform is an open information service that is continuously being developed. Comments on functionality, data quality, usability or thematic extensions help to optimize the service for the benefit of users. You can submit your suggestions informally via the contact page or special feedback forms.
#27
I am an information provider - can I cooperate with the portal?
Yes, the portal is open to content-related, technical or editorial cooperation, provided that this contributes to the quality, relevance or dissemination of the offering. If you offer content, interfaces or services that could be useful in the context of stock market-related information, we would be pleased to hear from you. The platform offers flexible integration options and a professional environment for quality-assured content.
#28
Can the platform technology also be used for other applications or partners?
Yes, the platform is based on a modular, scalable infrastructure that can be adapted to different information contexts and industry models. Technical components such as data aggregation, structuring logic, classification mechanisms and semantic filters can also be made available for external projects or individual applications on request. Please contact us for cooperation or license models.
#29
Can the underlying company data also be licensed or reused?
Structured access to selected master data of listed companies - such as GICS mapping, ISIN mapping, news feeds or metadata filters - is generally possible. The offer is aimed in particular at information service providers, research platforms or data-driven financial applications. Data can be provided via defined interfaces (e.g. API) or exportable formats, depending on the intended use and license framework.
#30
What forms of cooperation with external partners are conceivable?
Basically open. Possible forms of cooperation range from technical integrations and shared data models to content syndication or white label solutions. Partnerships with institutions that are looking for access to quality-assured data, dynamically structured news or sector-specific analyses - for example in the FinTech, media or research environment - are particularly interesting. We look forward to hearing from business development or product management departments.
#31
Why does this portal differ technically and conceptually from other information offerings?
Because no one from outside the industry is trying to understand the financial market here - but because the know-how comes from the heart of the financial world. The technical platform was developed by a team that combines in-depth market knowledge with innovative system design. The result: information architecture with real relevance, not shop window technology.
#32
What makes the technical solution particularly interesting for operators of their own financial portals?
In addition to high adaptability, the platform impresses with its modular structure and the consistent implementation of industry-specific logic - from GICS mapping to metadata filtering. For providers who operate their own information portals, sector-specific data structures, news feeds or visualizations can be quickly integrated on this basis - either as a white label, API module or embedded solution.
#33
Why can a collaboration go beyond traditional development services?
Because we don't just program, we think: The technological implementation is based on a deep understanding of market cycles, regulations, data formats and investor needs. Anyone who cooperates with this platform benefits from a sparring partner at eye level - both technically and professionally. This creates added value that goes far beyond pure IT expertise.
#34
Note on copyright and the processing of original content
The corporate news presented on this information portal is based on publicly accessible sources such as BusinessWire, GlobeNewswire, PR Newswire or comparable news services. The content is processed as part of an automated or editorially supported structuring process without changing, shortening or reinterpreting the content of the original information. This is so-called "as is" information, the form and content of which corresponds to the originally published announcement. The rights to the original texts remain unrestrictedly with the respective publishers or copyright holders. This portal merely assumes a structural categorization and allocation within the framework of a news-journalistic offer. Independent commercial reuse, systematic reproduction or other use of the content by third parties is only permitted within the framework of the statutory provisions or with the consent of the copyright holder.
About GICS Financials
GICS Financials is part of the GICS Eleven information portfolio, which focuses primarily on information from listed companies in the banking, insurance, brokerage sector.
About GICS Eleven

GICS Eleven (G11, GICS11) bundles topic-specific content and enables quick access to relevant information thanks to its gate function. The project is largely based on the Global Industry Classification Standard (GICS®), which was developed by MSCI and Standard & Poor's and enables a breakdown into sectors. GICS® consists of 11 sectors, 24 industry branches, 69 industries and 158 sub-industries.

GICS® is a registered trademark of MSCI Inc. and S&P Dow Jones Indices.

Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Friday, 23.01.2026, Calendar Week 04, 23rd day of the year, 342 days remaining until EoY.